From individual risk factors and the metabolic syndrome to global cardiometabolic risk
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
‘Traditional’ risk factors such as hypertension, elevated cholesterol, smoking, and diabetes have long been linked to cardiovascular disease (CVD). However, although remarkable progress has been made in the management of these classical CVD risk factors, obesity, the metabolic syndrome, and type 2 diabetes have reached such epidemic proportions that CVD remains a major cause of morbidity and mortality worldwide. As obesity rates soar, more and more patients are developing additional metabolic abnormalities that raise their CVD risk. Though obesity’s health hazards are well documented, physicians are sometimes perplexed by the absence of complications in some very obese patients. Equally perplexing is the fact that some moderately overweight individuals are characterized by a whole cluster of atherogenic and diabetogenic metabolic abnormalities. Because body mass index (BMI) provides little information about the location of body fat, calculating BMI as the ratio of weight over height-squared is therefore only useful as an initial step towards crudely classifying patients based on their relative weight. In this regard, numerous studies in the last two decades have confirmed that a high amount of abdominal fat, intra-abdominal (or visceral) adipose tissue in particular, is linked to a cluster of emerging metabolic risk factors/markers that may increase the risk of type 2 diabetes, CVD, and related mortality beyond excess body weight. The scientific and medical community’s recent recognition of abdominal obesity (especially the form characterized by excess visceral/ectopic fat) as the most prevalent form of the clustering atherothrombotic-inflammatory abnormalities associated with insulin resistance is an important conceptual advance with very significant clinical and public health implications. However, yet to be resolved is the extent to which the specific clustering abnormalities of visceral obesity increase overall CVD and type 2 diabetes risk estimated by traditional risk factors. There is evidence to suggest that current risk assessment algorithms may not accurately estimate the global CVD risk in patients with visceral obesity. In light of this, better methods are needed to assess the global risk of CVD and type 2 diabetes in the presence of traditional risk factors and emerging markers found in individuals with excess intra-abdominal adiposity and a ‘dysfunctional’ adipose tissue phenotype. This global risk is defined as cardiometabolic risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 2×
“This weight loss prevented (or at least delayed by several years) the conversion to type 2 diabetes among high-risk obese individuals with glucose intolerance.(77,78) Such lifestyle modification programmes have also been shown to reduce the risk of developing the metabolic syndrome.”
BackgroundSubcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961
(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876 · cited 2×
“The results of the Heart Protection Study (HPS) in diabetic patients provide a simple illustration of this notion.(71) Although all diabetic patients in the HPS benefited from simvastatin therapy, Individual risk factors and metabolic syndrome B29”
BackgroundResultMetabolic Syndrome and Risk of Incident Cardiovascular Events and Death
Gami, A. S., Witt, B. J., Howard, D. E., Erwin, P. J., Gami, L. A., Somers, V. K., & Montori, V. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.032 · Cited by 1,888
Assmann, G., Cullen, P., & Schulte, H. (2002) · Circulation · doi:10.1161/hc0302.102575 · Cited by 1,541 · cited 1×
“To assess absolute CHD risk, physicians must consider classical CHD risk factors such as age, sex, blood pressure, lipids (LDL-cholesterol, HDL-cholesterol), smoking, and diabetes and should also use the global CHD risk calculators such as those provided by the Framingham or PROCAM algorithms.(69,70) It has been sugge…”
MethodAlexander, C. M., Landsman, P. B., Teutsch, S. M., & Haffner, S. M. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1210 · Cited by 1,475 · cited 1×
“Although type 2 diabetics are clearly at greater risk of CHD than nondiabetics, recent studies have shown that type 2 diabetes is a heterogeneous entity and that the more abdominally obese the type 2 diabetic patients are, the greater is the likelihood that they have the features of the metabolic syndrome.(33) Consequ…”
BackgroundRoss, R., Dagnone, D., Jones, P. J. H., Smith, H., Paddags, A., Hudson, R., & Janssen, I. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-2-200007180-00008 · Cited by 1,435
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · cited 1×
“Moreover, rimonabant treatment increased plasma adiponectin levels, the increase being greater than what could be predicted by weight loss.(87) As CB1 receptors are found in adipose tissue as well as liver, gut, skeletal muscle, and beta cells, further studies will examine the tissue-specific effects of the CB1 antago…”
BackgroundSelf-citation
Cited by
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
“A full discussion of cardiometabolic risk is beyond the scope of the present paper and can be found in several previous reviews (109, 112, 113, 117, 232, 509).”
BackgroundMethodResultInfluentialSelf-citationLevels of vitamin D and cardiometabolic disorders: Systematic review and meta-analysis
Parker, J., Hashmi, O., Dutton, D., Mavrodaris, A., Stranges, S., Kandala, N.-B., Clarke, A., & Franco, O. H. (2010) · Maturitas · doi:10.1016/j.maturitas.2009.12.013 · Cited by 454
Poirier, P., Cornier, M.-A., Mazzone, T., Stiles, S., Cummings, S., Klein, S., McCullough, P. A., Ren Fielding, C., & Franklin, B. A. (2011) · Circulation · doi:10.1161/cir.0b013e3182149099 · Cited by 339
Self-citationOnat, A., Hergenç, G., Yüksel, H., Can, G., Ayhan, E., Kaya, Z., & Dursunoğlu, D. (2009) · Clinical Nutrition · doi:10.1016/j.clnu.2008.10.006 · Cited by 310
Meng, H., Zhu, L., Kord-Varkaneh, H., O Santos, H., Tinsley, G. M., & Fu, P. (2020) · Nutrition · doi:10.1016/j.nut.2020.110801 · Cited by 146
Metadata
- Authors
- Després, J.-P., Poirier, P., Bergeron, J., Tremblay, A., Lemieux, I., & Alméras, N.
- Venue
- European Heart Journal Supplements
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-01
- Volume
- 10
- Issue
- suppl_B
- Pages
- B24-B33
- ISSN
- 1520-765X (ISSN-L)
- 1554-2815
- 1520-1554
- OpenAlex
- W2140788156
- Cited by
- 46
- References
- 24
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: From individual risk factors and the metabolic syndrome to global cardiometabolic risk. https://app.cochat.ai/papers/10.1093/eurheartj/sum041
- The paper
- Després, J.-P., Poirier, P., Bergeron, J., Tremblay, A., Lemieux, I., & Alméras, N. (2008). From individual risk factors and the metabolic syndrome to global cardiometabolic risk. European Heart Journal Supplements. https://doi.org/10.1093/eurheartj/sum041
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.